The use of the word “survivor” can arouse strong feelings

In his latest epistle on living with cancer on MedPage Today, Howard Wolinsky addresses what he has come to understand is a very sensitive topic. … READ MORE …

Does TRT really delay biochemical recurrence after radical prostatectomy (in selected patients)?

Some data presented a few weeks ago at the annual meeting of the European Association for Urology appear to have surprised not only the study’s authors, but pretty much everyone else as well. … READ MORE …

Agent Orange and prostate cancer-specific survival on ADT

A newly published article in this month’s Journal of Urology has suggested that being exposed to Agent Orange and getting prostate cancer comes with better overall survival data than if one gets prostate cancer some other way. … READ MORE …

No mortality benefit from dietary supplements … says Harvard and Tufts

The issue of whether routine use of dietary supplements has any meaningful therapeutic benefit has long been a controversial issue (and we don’t expect that to change as a result of what appears below, but …) … READ MORE …

FDA approves new type of PSA testing methodology

According to a report on the US Food and Drug Administration (FDA) web site, the FDA has just approved the “finger-prick” Sangia Total PSA blood test developed by OPKO Diagnostics. … READ MORE …

Next-generation imaging in the management of advanced prostate cancer

A new article in the most recent issue of the Journal of Urology provides recommendations for clinicians as to the appropriate, current use of “next-generation” imaging in the treatment of advanced prostate cancer. … READ MORE …

Curing mice with prostate cancer!

So some readers will already have seen the article in today’s New York Times entitled “Cancer’s trick for dodging the immune system“. … READ MORE …

Restore – a clinical trial for MsM with prostate cancer

The Restore study is a new, NIH/NCI-funded, clinical trial designed to explore what will help gay, bisexual, and other men who have sex with men (collectively, MsM) to recover urinary, sexual, and erectile function after treatment for prostate cancer. … READ MORE …

“To DRE or not to DRE, that is the question”

With apologies to the Bard of Avon and his character Hamlet, the above-misquoted Prince of Denmark, we bring to your attention the most recent article by our good friend Howard Wolinsky on issues related to prostate cancer. … READ MORE …

For those considering treatment with a checkpoint inhibitor

We have heard a lot about treatment with checkpoint inhibitors over the past two or three years. When they work well, they can work very well indeed, but these drugs come with significant risk for side effects, and some of those side effects can be very serious. … READ MORE …

Phase III trial of olaparib in first-line treatment of mCRPC

Unfortunately we don’t always hear about some interesting clinical trials as early as we would like to. The following is a case in point. … READ MORE …

New prostate cancer imaging techniques and their use in clinical practice

An article by Vapiwala et al., just published in the Journal of Clinical Oncology, is a “must read” for patients who are trying to understand how new types of imaging technology are being applied in the diagnosis, work-up, and monitoring of men with various stages of prostate cancer. … READ MORE …

Darolutamide (ODM-201) in the treatment of nmCRPC

Earlier this year we had reported on the initial presentation of data demonstrating the efficacy and safety of darolutamide (formerly known as ODM-201), a third “super-antiandrogen” — similar to enzalutamide (Xtandi) and apalutamide (Erleada), in the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

How prostate cancer may “infect” normal prostate cells

There is a constant stream of scientific papers that focus on the possible ways that prostate cancer may start to spread within the prostate and then elsewhere. … READ MORE …

“Long-term” data on FLA in the treatment of localized prostate cancer

An important new paper in the Journal of Vascular and Interventional Radiology has just provided us with the first large set of data on the outcomes of men with prostate cancer treated with focal laser ablation (FLA). … READ MORE …